2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 594

Do Bone Marrow Edema Lesions in the Sacroiliac Joint Change into Fatty Lesions over a 1-Year Period in Patients with Axial Spondyloarthritis or Possible Spondyloarthritis
Abstract Number: 574

Do Extra-Articular Manifestations Influence Outcome in Ankylosing Spondylitis? a 12 Year Follow-up Study
Abstract Number: 2060

Do Fibromyalgia Patients Have a Distinct Sleep Signature?
Abstract Number: 1467

Do G-CSF and Neutrophils Contribute to the Pathophysiology of Rheumatoid Arthritis?
Abstract Number: 2018

Do Mediterranean or Vegetarian Diets Influence Risk of Rheumatoid Arthritis?
Abstract Number: 2599

Do Patients Diagnosed As Axial Spondyloarthritis (AxSpA) Who Have Primary Inefficacy to Anti-TNF Really Have AxSpA? a Five-Year Follow-up Study of 27 Patients with Primary Inefficacy to Anti-TNF
Abstract Number: 1182

Do Patients with Active RA Also Have Inflamed Atherosclerotic Plaques on PET-MRI?
Abstract Number: 2574

Do Patients with Axial Spondyloarthritis (AxSpA) Perform Enough Physical Activity? a Cross-Sectional Study of 207 Patients
Abstract Number: 491

Do Patients with Congestive Heart Failure Treated with Biologics for RA Have a Lower Risk of Fatal Outcome of Serious Infections?
Abstract Number: 2940

Do Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Respond Similarly Well to Nsaids? – a Prospective Study Including Magnetic Resonance Imaging
Abstract Number: 2416

Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice
Abstract Number: 2554

Do TNF Alpha Inhibitors Have an NSAID Sparing Effect in Real Life in Early Axial Spa? Results from the DESIR Cohort
Abstract Number: 132

Do Ultrasound (PDUS) and DAS28 Measure Different Aspects of Disease Activity? Analyses from the First Prospective International Phase IIIb Study of PDUS Response in Abatacept-Treated Patients with Rheumatoid Arthritis (RA)
Abstract Number: 2608

Do You Assess Gastro-Intestinal Auto-Antibodies and Symptoms in Patients with Spondyloarthritis?
Abstract Number: 351

Doctor, Will My Fatigue be Better If I’m in Remission? an Exploratory Analysis of 1284 Rheumatoid Arthritis (RA) Patients Indicates Fatigue Is the Only Aspect of Patient-Perceived Impact to Remain Significant in ACR/EULAR Boolean Remission

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].